What are the recommended diagnostic steps and treatment options for a patient with low plasma renin activity, low aldosterone, and an elevated aldosterone-to-renin ratio?

Your Lab Values Do NOT Meet Criteria for Primary Aldosteronism and Require Further Evaluation

With a renin activity of 0.12 ng/mL/h, aldosterone of 8 ng/dL, and an aldosterone-to-renin ratio (ARR) of 66.7, you have suppressed renin but your aldosterone level is too low to diagnose primary aldosteronism—this pattern requires investigation for other causes of low-renin hypertension and consideration of medication effects or alternative diagnoses.

Why This Doesn't Meet Primary Aldosteronism Criteria

Your results show a biochemical pattern that is incomplete for primary aldosteronism:

• Suppressed renin: Your PRA of 0.12 ng/mL/h is clearly suppressed (normal threshold is ≥1.0 ng/mL/h) 1, 2
• Elevated ARR: Your ratio of 66.7 exceeds the screening cutoff of 30 1, 3
• BUT—critically low aldosterone: Your aldosterone of 8 ng/dL falls below the required threshold of ≥10 ng/dL needed to interpret a positive ARR 1, 3, 2

The 2017 ACC/AHA guidelines explicitly state that plasma aldosterone concentration should be at least 10 ng/dL to interpret the ARR test as positive 1. The most recent 2025 Endocrine Society guideline reinforces this, requiring aldosterone ≥10 ng/dL (≥277 pmol/L) when measured by immunoassay 2.

Critical Next Steps: Rule Out Interfering Factors

1. Medication Review (HIGHEST PRIORITY)

Before any further workup, assess for medications that suppress aldosterone:

• Mineralocorticoid receptor antagonists (spironolactone, eplerenone): Must be withdrawn for at least 4 weeks before testing 1, 3
• ACE inhibitors or ARBs: Should be held 4, 5
• Beta-blockers: Can suppress renin and should be discontinued 4, 5
• Clonidine: Should be avoided during testing 4, 5

2. Verify Testing Conditions

Ensure the sample was collected properly:

• Morning sample, sitting position after 15 minutes of rest 4, 5, 6
• Unrestricted salt intake (not on low-sodium diet) 1
• Normal serum potassium (hypokalemia suppresses aldosterone; correct to normal range and retest) 1, 2

3. Repeat Testing After Optimization

Once interfering medications are withdrawn (4+ weeks for MRAs) and potassium is normalized:

• Remeasure aldosterone, renin, and ARR under standardized conditions
• Check serum potassium simultaneously 2

Differential Diagnosis for Low-Renin, Low-Aldosterone Pattern

If repeat testing confirms persistently low renin AND low aldosterone, consider:

Non-Aldosterone Mineralocorticoid Excess Syndromes

• Liddle syndrome: Genetic disorder causing constitutive activation of epithelial sodium channels 7
• Apparent mineralocorticoid excess (AME): Deficiency of 11β-hydroxysteroid dehydrogenase type 2
• Exogenous mineralocorticoid exposure: Licorice ingestion, carbenoxolone
• Cushing syndrome: Check 24-hour urinary free cortisol or overnight dexamethasone suppression test 8

Essential Low-Renin Hypertension

• Approximately 47% of hypertensive patients with adrenal incidentalomas have suppressed renin even with aldosterone 5-10 ng/dL 9
• In therapy-resistant hypertension, 67% have low renin status (PRA <0.5 nmol/L/h) 10
• This represents a spectrum of mild renin-independent aldosterone activity

Treatment Approach Based on Current Evidence

If Hypertensive with This Biochemical Pattern:

Even without confirmed primary aldosteronism, low-renin hypertension responds preferentially to aldosterone-targeted therapy 9, 10, 11:

1. First-line: Mineralocorticoid receptor antagonists

   • Spironolactone 25-50 mg daily OR eplerenone 50-100 mg daily 1, 8
   • Recent evidence shows patients with suppressed renin and aldosterone 5-10 ng/dL achieve significant BP reduction (-18 mmHg systolic) with MRA therapy 9

2. Alternative: Epithelial sodium channel (ENaC) inhibitors

   • Amiloride 5-10 mg daily, often combined with hydrochlorothiazide
   • In low-renin resistant hypertension, amiloride/HCTZ reduced BP by 31/15 mmHg compared to placebo 10

3. Thiazide diuretics as adjunct therapy 11

Monitor Treatment Response:

• Blood pressure reduction
• Potassium levels (watch for hyperkalemia with MRAs)
• Renin levels should increase with effective MRA therapy 9
• If BP escapes control, increase MRA dose rather than adding vasodilators 10

Common Pitfalls to Avoid

1. Don't proceed to confirmatory testing (saline suppression, fludrocortisone test) with aldosterone <10 ng/dL—you don't meet screening criteria 1, 2

2. Don't order adrenal imaging or adrenal venous sampling without first establishing the diagnosis biochemically 1, 6

3. Don't assume the elevated ARR alone is diagnostic—the ARR can be falsely elevated when renin is very low, which is why the absolute aldosterone threshold exists 1, 3

4. Don't overlook medication interference—this is the most common reason for confusing results 2

5. Don't ignore the therapeutic opportunity—even if this doesn't represent classic primary aldosteronism, low-renin hypertension benefits from mechanism-based treatment targeting sodium retention 9, 11

Summary Algorithm

1. Review and withdraw interfering medications (especially MRAs for 4+ weeks)
2. Correct hypokalemia if present
3. Repeat aldosterone, renin, and ARR under proper conditions
4. If aldosterone remains <10 ng/dL: Consider alternative diagnoses (Liddle, AME, Cushing's) and empiric trial of MRA or amiloride for low-renin hypertension
5. If aldosterone ≥10 ng/dL on repeat: Proceed to confirmatory testing for primary aldosteronism 1, 2